A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Clinical trial NCT00911898 · COMPLETED

Trial details

NCT number: NCT00911898
Sponsor: Merrimack Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Her2 Amplified Solid Tumors Metastatic Breast Cancer

Start date: 2009-06-01
Primary completion: 2012-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.